IP Library › Granted Patent US 12,251,392
Granted Patent B2
US 12,251,392 · App. 18/138,432 · Granted Mar 18, 2025

Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes

Inventors: Michio Hirano (New York, NY); Caterina Garone (Cambridge, GB); Ramon Marti (Barcelona, ES)
Assignee: The Trustees of Columbia University in the City of New York
A61K31/7072A61K9/0053A61K31/513A61K31/7068A61K31/7076A61K31/708A61K45/06A61P21/00A61P43/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,251,392
App. No.
18/138,432
Granted
Mar 18, 2025
Kind
B2
Abstract

The invention relates generally to a pharmacological therapy for human genetic diseases, specifically those characterized by unbalance nucleotide pools, more specifically mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency. The pharmacological therapy involves the administration of at least one deoxynucleoside, or mixtures thereof. For the treatment of TK2 deficiency, the pharmacological therapy involves the administration of either deoxythymidine (dT) or deoxycytidine (dC), or mixtures thereof. This administration of deoxynucleosides is applicable to other disorders of unbalanced nucleotide pools, especially those found in mitochondrial DNA depletion syndrome.

Claims (9)

1. A method of treating mitochondrial DNA depletion syndrome in a human subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising at least one deoxynucleoside, wherein the mitochondrial DNA depletion syndrome is characterized by at least one mutation in a gene which is DGUOK and wherein the therapeutically effective amount is between about 200 mg/kg/day and 600 mg/kg/day of the at least one deoxynucleoside in the composition and the composition is administered to the subject parenterally.

2. The method of claim 1 , wherein the composition is administered intravenously.

3. The method of claim 1 , wherein the composition is administered one time a day, two times a day, three times daily, four times daily, five times daily or six times daily.

4. A method of treating mitochondrial DNA depletion syndrome in a human subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising at least one deoxynucleoside, wherein the mitochondrial DNA depletion syndrome is characterized by at least one mutation in a gene chosen from the group consisting of: TYMP and RRM2B and wherein the therapeutically effective amount is between about 200 mg/kg/day and 600 mg/kg/day of the at least one deoxynucleoside in the composition and the composition is administered to the subject parenterally.

5. The method of claim 4 , wherein the composition is administered intravenously.

6. The method of claim 4 , wherein the composition is administered one time a day, two times a day, three times daily, four times daily, five times daily or six times daily.

7. A method of treating mitochondrial DNA depletion syndrome in a human subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising at least one deoxynucleoside, wherein the mitochondrial DNA depletion syndrome is characterized by at least one mutation in a gene chosen from the group consisting of: TK2, DGUOK; TYMP; and RRM2B and wherein the therapeutically effective amount is between about 200 mg/kg/day and 600 mg/kg/day of the at least one deoxynucleoside in the composition and the composition is administered to the subject intrathecally.

8. The method of claim 1 , wherein the composition comprises dG and/or dA.

9. The method of claim 4 , wherein the composition comprises dA, dG, dC, or dT, or mixtures thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2023
From: GARONE, CATERINA; HIRANO, MICHIO
To: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Reel/Frame 063419/0293 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2023
From: FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON-INSTITUT DE RECERCA
To: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Reel/Frame 063419/0427 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2023
From: MARTI, RAMON
To: FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON-INSTITUT DE RECERCA
Reel/Frame 063447/0751 →
Continuity (5)
Division 17242822 · Apr 28, 2021
Continuation 16583852 · Sep 26, 2019
Continuation 15736092
Provisional Application 62180914 · Jun 17, 2015
Related Publication 20230277577A1 · Sep 7, 2023
References Cited (78)
US 6596700B2 · Sommadossi · 2003 [cited by applicant]
US 10292996B2 · Hirano et al. · 2019 [cited by applicant]
US 10471087B2 · Hirano · 2019 [cited by examiner]
US 11110111B2 · Hirano · 2021 [cited by examiner]
US 11666592B2 · Hirano · 2023 [cited by examiner]
EA 005890 · 2005 [cited by applicant]
EP 3302499 · 2018 [cited by applicant]
RU 2300381 · 2007 [cited by applicant]
WO WO20120125848 · 2012 [cited by applicant]
Glick, et al., “Molecular Biotechnology: Principles and Applications”, Moscow, “Mir”, 2002, p. 103, Reference is believe to predate application priority date. [cited by applicant]
Saada et al., “Mitochondrial deoxyribonucleotide pools in deoxyguanosine kinase deficiency”, Molecular Genetics and Metabolism. Academic Press. Amsterdam. NL. vol. 95. No. 3. Nov. 1, 2008 (Nov. 1, 2008). pp. 169-173. XP… [cited by applicant]
Cowan M J et al: “Deoxycytidine therapy in two patients with adenosine deaminase deficiency and severe immunodeficiency disease”, Clinical Immunology and Immunopathology, San Diego, CA, US, vol. 37, No. 1, Oct. 1, 1985 … [cited by applicant]
Y. Camara et al: “Administration of deoxyribonucleosides or inhibition of their catabolism as a pharmacological approach for mitochondrial DNA depletion syndrome”, EPO Form 1703 01.91TRI Human Molecular Genetics, vol. 2… [cited by applicant]
Julia Wang et al: “TK2-Related Mitochondrial DNA Maintenance Defect, Myopathic Form—GeneReviews—NCBI Bookshelf” In: “Gene Reviews”, Dec. 6, 2012 (Dec. 6, 2012), XP055520605. [cited by applicant]
Steve Perrin: “Make mouse studies work” Nature, vo. 507, p. 423-425, Mar. 27, 2014. [cited by applicant]
NIH Research Portfolio ONline Reporting Tools (RePORT), project #3—Pharmacological and gene therapy of TK2 deficiency in mice and human, Michio Hirano (accessed Jan. 30, 2018). [cited by applicant]
Garone et al., “Deoxypyrimidine monophosphates treatment for thymidine kinase 2 deficiency”, Neurology, suppl. MeetingAbstracts 80.1, 65th American Acadamy of Neurology Annual Meeting, (Feb. 12, 2013), accessed Jan. 30,… [cited by applicant]
Akman, Hasan O. “Thymidine kinase 2 (H126N) knockin mice show the essential role of balanced deoxynucleotide pools for mitochondrial DNA maintenance”, Human Molecular Genetics, May 8, 2008, vol. 17, No. 16, pp. 2433-244… [cited by applicant]
Longley, et al. (May 4, 2006). Mutant POLG2 disrupts DNA polymerase gamma subunits and causes progressive external ophthalmoplegia. Am J Hum Genet. 78:1026-1034. [cited by applicant]
Martí, et al. (2012b) Assessment of thymidine phosphorylase function: measurement of plasma thymidine (and deoxyuridine) and thymidine phosphorylase activity. Methods Mol. Biol. 837: 121-133. Available online Dec. 20, 2… [cited by applicant]
Nishino, et al. (Jan. 29, 1999). Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 283:689-692. [cited by applicant]
Ronchi, et al. (Jul. 30, 2012). Next-generation sequencing reveals DGUOK mutations in adult patients with mitochondrial DNA multiple deletions. Brain 135:3404-3415. [cited by applicant]
Sarzi, et al. (Jul. 6, 2007) Twinkle helicase (PEO1) gene mutation caused mitochondrial DNA depletion. Ann. Neurol. 62: 579-587. [cited by applicant]
Spelbrink, et al. (Jul. 2001). Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nature Genet. 28:223-231. [cited by applicant]
Tyynismaa, et al. (Aug. 14, 2009). A heterozygous truncating mutation in RRM2B causes autosomal-dominant progressive external ophthalmoplegia with multiple mtDNA deletions. Am. J. Hum. Genet. 85: 290-295. [cited by applicant]
Van Goethem, et al. (Jul. 2001) Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nature Genet. 28:211-212. [cited by applicant]
Akman, et al. (May 6, 2008) Thymidine kinase 2 (H126N) knock in mice show the essential role of balanced deoxynucleotide pools for mitochondrial DNA maintenance. Hum Mol Genet 17:2433-2440. [cited by applicant]
Alston, et al. (Dec. 3, 2013) Late-onset respiratory failure due to TK2 mutations causing multiple mtDNA deletions. Neurology. 81:2051-3. [cited by applicant]
Bartesaghi, et al. (Jan. 26, 2010) Loss of thymidine kinase 2 alters neuronal bioenergetics and leads to neurodegeneration. Hum Mol Genet. 19:1669-77. [cited by applicant]
Blakely, et al. (Apr. 14, 2008) Novel mutations in the TK2 gene associated with fatal mitochondrial DNA depletion myopathy. Neuromuscular Disorders 18:557-560. [cited by applicant]
Bourdon, et al. (May 7, 2007) Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet 39: 776-780. [cited by applicant]
Carrozzo, et al. (Jan. 30, 2003) Mutation analysis in 16 patients with mtDNA depletion. Hum Mutat 21:453-454. [cited by applicant]
Chanprasert, et al. (Jul. 10, 2013) Molecular and clinical characterization of the myopathic form of mitochondrial DNA depletion syndrome caused by mutations in the thymidine kinase (TK2) gene. Mol Genet Metab. 110:153-… [cited by applicant]
Chanprasert, et al. (Dec. 6, 2012) TK2-Related Mitochondrial DNA Depletion Syndrome, Myopathic Form. GeneReviews® Internet. [cited by applicant]
Collins, et al. (Aug. 4, 2009) Progressive myofiber loss with extensive fibro-fatty replacement in a child with mitochondrial DNA depletion syndrome and novel thymidine kinase 2 gene mutations. Neuromuscular Disorders 1… [cited by applicant]
Copeland (Mar. 21, 2008) Inherited mitochondrial diseases of DNA replication. Ann. Rev. Med. 59:131-146. [cited by applicant]
DiMauro, et al. (Feb. 20, 1987) Cytochrome c oxidase deficiency in Leigh syndrome. Ann Neurol 22: 498-506. [cited by applicant]
DiMauro, Schon. (Jul. 1, 2003) Mitochondrial respiratory-chain diseases. N Engl J Med 348:2656-2668. [cited by applicant]
DiMauro, Hirano. (2005) Mitochondrial encephalomyopathies: an update. Neuromuscul Disord 15:276-286. Accepted Dec. 10, 2004. [cited by applicant]
Dorado, et al. (2011) Onset and organ specificity of Tk2 deficiency depends on Tk1 down-regulation and transcriptional compensation. Hum Mol Genet. 20:155-64. Accepted Oct. 6, 2010. [cited by applicant]
Elpeleg, et al. (Apr. 7, 2005) Deficiency of the ADP-forming succinyl-CoA synthase activity is associated with encephalomyopathy and mitochondrial DNA depletion. Am J Hum Genet 76: 1081-1086. [cited by applicant]
Ferraro, et al. (2010) Quantitation of cellular deoxynucleoside triphosphates. Nucleic Acids Research 38: e85. Accepted Nov. 18, 2009. [cited by applicant]
Galbiati, et al. (2006) New mutations in TK2 gene associated with mitochondrial DNA depletion. Pediatr Neurol 34: 177-185. Accepted Jul. 11, 2005. [cited by applicant]
Garone, et al. (Sep. 10, 2012). MPV17 Mutations Causing Adult-Onset Multisystemic Disorder With Multiple Mitochondrial DNA Deletions. Arch Neurol 69:1648-1651. [cited by applicant]
Gotz, et al. (Sep. 3, 2008) Thymidine kinase 2 defects can cause multi-tissue mtDNA depletion syndrome. Brain 131:2841-2850. [cited by applicant]
Hirano, et al. (Dec. 2001) Defects of intergenomic communication: autosomal disorders that cause multiple deletions and depletion of mitochondrial DNA. Semin Cell Develop Biol 12:417-427. [cited by applicant]
Leshinsky-Silver, et al. (2008) A defect in the thymidine kinase 2 gene causing isolated mitochondrial myopathy without mtDNA depletion. Eur J Paediatr Neurol 12:309-13. Accepted Sep. 2, 2007. [cited by applicant]
Lesko, et al. (2010) Two novel mutations in thymidine kinase-2 cause early onset fatal encephalomyopathy and severe mtDNA depletion. Neuromuscul Disord 20:198-203. Accepted Nov. 25, 2009. [cited by applicant]
Lopez, et al. (2009) Unbalanced deoxynucleotide pools cause mitochondrial DNA instability in thymidine phosphorylase deficient mice. Hum Mol Genet 18: 714-722. Accepted Nov. 19, 2008. [cited by applicant]
Mancuso, et al. (Jul. 2003) Mitochondrial myopathy of childhood associated with mitochondrial DNA depletion and a homozygous mutation (T77M) in the TK2 gene. Arch Neurol. 60:1007-9. [cited by applicant]
Mancuso, et al. (Jun. 20, 2002) Mitochondrial DNA depletion: mutations in thymidine kinase gene with myopathy and SMA. Neurology. 59:1197-202. [cited by applicant]
Mandel, et al. (Nov. 2001) The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nat Genet 29: 337-341. [cited by applicant]
Martí, et al. (Apr. 8, 2010) Hearing loss in a patient with the myopathic form of mitochondrial DNA depletion syndrome and a novel mutation in the TK2 gene. Pediatr Res. 68:151-4. [cited by applicant]
Martí, et al. (2012) Measurement of mitochondrial dNTP pools. Methods Mol Biol 837: 135-148. Dec. 20, 2011. [cited by applicant]
Naviaux, Nguyen. (Feb. 4, 2004) POLG mutations associated with Alpers' syndrome and mitochondrial DNA depletion. Ann Neurol 55: 706-712. [cited by applicant]
Oskoui, et al. (Aug. 2006) Clinical spectrum of mitochondrial DNA depletion due to mutations in the thymidine kinase 2 gene. Arch Neurol 63:1122-1126. [cited by applicant]
Ostergaard, et al. (Apr. 26, 2007) Deficiency of the alpha subunit of succinate-coenzyme A ligase causes fatal infantile lactic acidosis with mitochondrial DNA depletion. Am J Hum Genet 81: 383-387. [cited by applicant]
Paradas, et al. (2012) TK2 mutation presenting as indolent myopathy. Neurology 29:504-506. Jan. 9, 2013. [cited by applicant]
Roos, et al. (May 20, 2014) Mitochondrial DNA depletion in single fibers in a patient with novel TK2 mutations. Neuromuscul Disord. 24:713-20. [cited by applicant]
Saada, et al. (Oct. 22, 2001) Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nat Genet 29:342-344. [cited by applicant]
Saada, et al. (Aug. 7, 2003) Mitochondrial deoxyribonucleoside triphosphate pools in thymidine kinase 2 deficiency. Biochem Biophys Res Commun 310:963-966. [cited by applicant]
Spinazzola, et al. (Apr. 2, 2006) MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. Nat Genet 38: 570-575. [cited by applicant]
Tulinius, et al. (Mar. 6, 2005) Novel mutations in the thymidine kinase 2 gene (TK2) associated with fatal mitochondrial myopathy and mitochondrial DNA depletion. Neuromuscul Disord. 15:412-415. [cited by applicant]
Tyynismaa, et al. (2012) Thymidine kinase 2 mutations in autosomal recessive progressive exgternal ophthalmoplegia with multiple mitochondrial DNA deletions. Hum Mol Genet 21:66-75. Accepted Sep. 19, 2011. [cited by applicant]
Vilà, et al. (Apr. 2003) Reversion of mtDNA depletion in a patient with TK2 deficiency. Neurology 60:1203-1205. [cited by applicant]
Wang, et al. (2005) Molecular insight into mitochondrial DNA depletion syndrome in two patients with novel mutations in the deoxyguanosine kinase and thymidine kinase 2 genes. Mol Genet Metab. 84:75-82. Available online… [cited by applicant]
Garonoe et al., “Deoxypyrimidine monophosphate bypass therapy for thymidine kinase 2 deficiency”. EMBO Mol Med Jun. 26, 2014 vol. 6 No. 8 pp. 1016-1027. Especially abstract, p. 1016 col. 2, p. 1017 col. 1 para 2, para 2… [cited by applicant]
MedChem Express. Tipiracil hydrochloride (online) 2014 [retrieved Oct. 26, 2016] Available on the internet: <ULR: https://www.medchemexpress.com/Tipiracilhydrochloride.html?gclid=CjOKEQjwqMHABRDV16_hqKGDyNIBEiQAN-O9hEkN… [cited by applicant]
Camara et al. “Feeding the deoxyribonucleoside salvage pathway to rescue mitochondrial DNA”. Drug Discov Today Oct. 2013 vol. 18 No. 19-20 pp. 950-957. Especially p. 955 col. 5 para 3-4. [cited by applicant]
Garone et al., “Clinical and genetic spectrum of mitochondrial meurogastrointestinal encephalomyopathy”. Brain Nov. 2011 vol. 134 Pt 11 pp. 3326-3332. Especially p. 3328 col. 1 para 3. [cited by applicant]
Carver, Jane D. “Dietary nucleotides: cellular immune, intestinal and hepatic system effects.” The Journal of nutrition 124.suppl_1 (1994): 144S-148S. [cited by applicant]
Sonoda, Tomoko, and Masamiti Tatibana. “Metabolic fate of pyrimidines and purines in dietary nucleic acids ingested by mice.” Biochimica et Biophysica Acta (BBA)-Nucleic Acids and Protein Synthesis 521.1 (1978): 55-66. [cited by applicant]
Nogueira, Célia, et al. “Syndromes associated with mitochondrial DNA depletion.” Italian journal of pediatrics 40.1 (2014): 1-10. [cited by applicant]
Cámara, Yolanda, et al. “Feeding the deoxyribonucleoside salvage pathway to rescue mitochondrial DNA.” Drug discovery today 18.19-20 (Oct. 2013): 950-957. [cited by applicant]
https://grantome.com/grant/NIH/P01-HD080642-01-5121, May 31, 2015 publication date asserted by SIPO in counterpart China Divisional Patent Application No. 2023107576092, budget start date of Sep. 30, 2014. [cited by applicant]
Ramón et al., “Therapy Prospects for Mitochondrial DNA Maintenance Disorders,” Int. J. Mol. Sci., Jun. 16, 2021, vol. 22, No. 6447, 35 pages. [cited by applicant]
Dombi et al., “Nucleoside Supplements as Treatments for Mitochondrial DNA Depletion Syndrome,” Front. Cell Dev. Biol., Apr. 2, 2024, vol. 12, No. 1260496, 17 pages. [cited by applicant]
https://grantome.com/grant/NIH/P01-HD080642-01-5121, likely published in RePORTER on Monday Oct. 6, 2014 according to NIH RePORT Support Team. [cited by applicant]